Search
Pegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigationalPegcetacoplan is a complement inhibitor indicated in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). … [A235000,A235005] Pegcetacoplan is a pegylated C3 inhibitor that can disrupt the processes leading to both forms of hemolysis that threaten patients with PNH.
Products: EMPAVELI® 54 MG/ML SOLUCIÓN INYECTABLEPotassium gluconate
go.drugbank.com/drugs/DB13620ApprovedIt is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function [A32222]. … Potassium gluconate is a salt of [DB01345] and is classified as a food additive by the FDA [L2654]. It is also used as a potassium supplement [L2657]. Potassium is an essential nutrient.
Asunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnIt has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. … Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor.
Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Vandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. … On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Synonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Etretinate
go.drugbank.com/drugs/DB00926ApprovedWithdrawnEtretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. … Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at
Sonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Synonyms: N-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridin-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamideNedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalNedaplatin is a second generation platinum analog [A20300]. It is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.
Synonyms: (glycolato-O,O')diammineplatinum(II), cis-Diammine(glycolato)platinum(II)